Introduction: Type I interferons (IFNs) comprise a group of at least 13 structurally related subtypes of IFN-α with similar, but not identical, biological activities. Each subtype displays a unique activity profile; only IFN-α2a and IFN-α2b subtypes together with natural IFN-α preparations are currently used in the clinical practice, so that the remaining IFN-α subtypes are a still unexploited reservoir of opportunity also in the new era of direct-acting antiviral agents for the treatment of hepatitis C virus (HCV). Areas covered: This paper reviews recent progress in the study of the biology of IFN family, the antiviral action mechanism and the strategies employed by HCV to evade IFN action. Currently available IFN preparations for the treatment of chronic hepatitis C infection are described and what is currently known on the pharmacokinetics, pharmacodynamics and immunogenicity of IFN-α preparations used in clinical practice are summarized. Expert opinion: The characterization of multifunctional nature of IFN system together with recent advances in the identification of HCV IFN evasion strategies and the variety of host factors influencing IFN treatment response should be considered to improve HCV and other infectious diseases treatment in the future. © 2013 Informa UK, Ltd.

Antiviral activity of the interferon α family: biological and pharmacological aspects of the treatment of chronic hepatitis C / Scagnolari, Carolina; Antonelli, Guido. - In: EXPERT OPINION ON BIOLOGICAL THERAPY. - ISSN 1471-2598. - STAMPA. - 13:5(2013), pp. 693-711. [10.1517/14712598.2013.764409]

Antiviral activity of the interferon α family: biological and pharmacological aspects of the treatment of chronic hepatitis C.

SCAGNOLARI, CAROLINA;ANTONELLI, Guido
2013

Abstract

Introduction: Type I interferons (IFNs) comprise a group of at least 13 structurally related subtypes of IFN-α with similar, but not identical, biological activities. Each subtype displays a unique activity profile; only IFN-α2a and IFN-α2b subtypes together with natural IFN-α preparations are currently used in the clinical practice, so that the remaining IFN-α subtypes are a still unexploited reservoir of opportunity also in the new era of direct-acting antiviral agents for the treatment of hepatitis C virus (HCV). Areas covered: This paper reviews recent progress in the study of the biology of IFN family, the antiviral action mechanism and the strategies employed by HCV to evade IFN action. Currently available IFN preparations for the treatment of chronic hepatitis C infection are described and what is currently known on the pharmacokinetics, pharmacodynamics and immunogenicity of IFN-α preparations used in clinical practice are summarized. Expert opinion: The characterization of multifunctional nature of IFN system together with recent advances in the identification of HCV IFN evasion strategies and the variety of host factors influencing IFN treatment response should be considered to improve HCV and other infectious diseases treatment in the future. © 2013 Informa UK, Ltd.
2013
neutralizing antibody; interferon α; interferon-stimulated genes; interferon λ; microrna; hepatitis c virus; interleukin 28b
01 Pubblicazione su rivista::01a Articolo in rivista
Antiviral activity of the interferon α family: biological and pharmacological aspects of the treatment of chronic hepatitis C / Scagnolari, Carolina; Antonelli, Guido. - In: EXPERT OPINION ON BIOLOGICAL THERAPY. - ISSN 1471-2598. - STAMPA. - 13:5(2013), pp. 693-711. [10.1517/14712598.2013.764409]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/509880
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 22
  • ???jsp.display-item.citation.isi??? 18
social impact